These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 9552224)

  • 1. The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease.
    Satsangi J; Landers CJ; Welsh KI; Koss K; Targan S; Jewell DP
    Inflamm Bowel Dis; 1998 Feb; 4(1):18-26. PubMed ID: 9552224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significance of the determination of antineutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis and Crohn's disease].
    García-Herola A; Nos P; Hoyos M; Hinojosa J; Molés JR; Pascual S; Bustamante M; Sánchez Cuenca JM; Carmona E; Ponce J; Berenguer J
    Gastroenterol Hepatol; 1998 Apr; 21(4):169-73. PubMed ID: 9633176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup.
    Vasiliauskas EA; Plevy SE; Landers CJ; Binder SW; Ferguson DM; Yang H; Rotter JI; Vidrich A; Targan SR
    Gastroenterology; 1996 Jun; 110(6):1810-9. PubMed ID: 8964407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease.
    Mahler M; Bogdanos DP; Pavlidis P; Fritzler MJ; Csernok E; Damoiseaux J; Bentow C; Shums Z; Forbes A; Norman GL
    Clin Chim Acta; 2013 Sep; 424():267-73. PubMed ID: 23806819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers.
    Yang H; Rotter JI; Toyoda H; Landers C; Tyran D; McElree CK; Targan SR
    J Clin Invest; 1993 Aug; 92(2):1080-4. PubMed ID: 8349790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antineutrophil cytoplasmic antibodies in Japanese patients with inflammatory bowel disease: prevalence and recognition of putative antigens.
    Sugi K; Saitoh O; Matsuse R; Tabata K; Uchida K; Kojima K; Nakagawa K; Tanaka S; Teranishi T; Hirata I; Katsu K
    Am J Gastroenterol; 1999 May; 94(5):1304-12. PubMed ID: 10235211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic heterogeneity within ulcerative colitis determined by an interleukin-1 receptor antagonist gene polymorphism and antineutrophil cytoplasmic antibodies.
    Papo M; Quer JC; Gutierrez C; Broch M; Casellas F; Pastor RM; Olona M; Richart C
    Eur J Gastroenterol Hepatol; 1999 Apr; 11(4):413-20. PubMed ID: 10321759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-neutrophil cytoplasmic antibodies in chronic inflammatory bowel disease. Prevalence and diagnostic role.
    Hertervig E; Wieslander J; Johansson C; Wiik A; Nilsson A
    Scand J Gastroenterol; 1995 Jul; 30(7):693-8. PubMed ID: 7481534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients.
    Papp M; Altorjay I; Norman GL; Shums Z; Palatka K; Vitalis Z; Foldi I; Lakos G; Tumpek J; Udvardy ML; Harsfalvi J; Fischer S; Lakatos L; Kovacs A; Bene L; Molnar T; Tulassay Z; Miheller P; Veres G; Papp J; ; Lakatos PL
    Inflamm Bowel Dis; 2007 Aug; 13(8):984-92. PubMed ID: 17417801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and significance of perinuclear anti-neutrophil antibodies (pANCA) in Romanian patients with Crohn's disease and ulcerative colitis.
    Preda CM; Vermeire S; Rutgeerts P; Joosens S; Diculescu M; Marica C; Ciocarlan M; Mirea V; Oproiu A
    Rom J Gastroenterol; 2005 Dec; 14(4):357-60. PubMed ID: 16400351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease.
    Rump JA; Schölmerich J; Gross V; Roth M; Helfesrieder R; Rautmann A; Lüdemann J; Gross WL; Peter HH
    Immunobiology; 1990 Nov; 181(4-5):406-13. PubMed ID: 2099908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA antigens and anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease.
    García Herola A; Nos P; Hinijosa J; Hoyos M; Molés JR; Carmona E; Puig N; Sánchez-Cuenca JM; Ponce J; Berenguer J
    Rev Esp Enferm Dig; 2003 Nov; 95(11):760-4, 755-9. PubMed ID: 14640873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease.
    Walmsley RS; Zhao MH; Hamilton MI; Brownlee A; Chapman P; Pounder RE; Wakefield AJ; Lockwood CM
    Gut; 1997 Jan; 40(1):105-9. PubMed ID: 9155585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and immunological markers in pouchitis.
    Brett PM; Yasuda N; Yiannakou JY; Herbst F; Ellis HJ; Vaughan R; Nicholls RJ; Ciclitira PJ
    Eur J Gastroenterol Hepatol; 1996 Oct; 8(10):951-5. PubMed ID: 8930557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity.
    Abad E; Tural C; Mirapeix E; Cuxart A
    J Autoimmun; 1997 Apr; 10(2):175-80. PubMed ID: 9185879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha1-antitrypsin phenotypes and anti-neutrophil cytoplasmic auto-antibodies in inflammatory bowel disease.
    Taddei C; Audrain MA; Reumaux D; Sesboüe R; Testa A; Galmiche JP; Duthilleul P; Colombel JF; Esnault VL
    Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1293-8. PubMed ID: 10563543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
    Bansi DS; Chapman RW; Fleming KA
    Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):881-5. PubMed ID: 8889455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-neutrophil cytoplasmic antibodies (ANCA) in sera from patients with inflammatory bowel disease (IBD). Relation to disease pattern and disease activity.
    Broekroelofs J; Mulder AH; Nelis GF; Westerveld BD; Tervaert JW; Kallenberg CG
    Dig Dis Sci; 1994 Mar; 39(3):545-9. PubMed ID: 7510606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial and sporadic inflammatory bowel disease: comparison of clinical features and serological markers in a genetically homogeneous population.
    Halme L; Turunen U; Heliö T; Paavola P; Walle T; Miettinen A; Järvinen H; Kontula K; Färkkilä M
    Scand J Gastroenterol; 2002 Jun; 37(6):692-8. PubMed ID: 12126248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are HLA-DR or TAP genes genetic markers of severity in ulcerative colitis?
    Heresbach D; Alizadeh M; Reumaux D; Colombel JF; Delamaire M; Danze PM; Gosselin M; Genetet B; Bretagne JF; Semana G
    J Autoimmun; 1996 Dec; 9(6):777-84. PubMed ID: 9115580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.